Press Release: Q4 sales growth of 10.3%, 2024 business EPS

Jan 30, 2025 · Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales...

CouponFollow Extension

3%
OFF

Press Release: Q4 Sales Growth Of 10.3%, 2024 Business EPS

2 weeks from now

Jan 30, 2025 · Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales...

globenewswire.com

3%
OFF

Sanofi: Q4 Sales Growth Of 10.3%, 2024 Business EPS Guidance …

2 weeks from now

Jan 30, 2025 · 5 In 2025, sales growth will exclude any impact from hyperinflation. In 2024, it is estimated that sales growth benefited by 1.8 percentage points. 6 Applying average January …

sanofi.com

3%
OFF

Press Release: Q4 Sales Growth Of 10.3%, 2024 Business EPS …

2 weeks from now

Jan 30, 2025 · Q4: sales growth of 10.3% at CER 1 and business EPS 2 of €1.31. Pharma launches up 56.5%, reaching sales of €0.8 billion, 8% of total sales, led by ALTUVIIIO; …

morningstar.com

3%
OFF

Sanofi: Q4 Sales Growth Of 10.3%, 2024 Business EPS Guidance …

2 weeks from now

Jan 30, 2025 · We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already contributed 11 …

pharmiweb.com

3%
OFF

Press Release: Q4 Sales Growth Of 10.3%, 2024 Business EPS …

2 weeks from now

30 Jan 2025 06:30. Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025

lse.co.uk

3%
OFF

Press Release: Q4 Sales Growth Of 10.3%, 2024 Business EPS …

2 weeks from now

Jan 30, 2025 · Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales growth of …

marketscreener.com

3%
OFF

Press Release: Q4 Sales Growth Of 10.3%, 2024 Business EPS …

2 weeks from now

Jan 30, 2025 · Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales growth

einnews.com

3%
OFF

Press Release: Q4 Sales Growth Of 10.3%, 2024 Business EPS …

2 weeks from now

Jan 30, 2025 · Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025

chroniclejournal.com

3%
OFF

Earnings Call Transcript: Sanofi Q4 2024 Sees Strong Growth In

2 weeks from now

Q4 2024 net sales increased by 10.3% to 10.6 billion euros. Business EPS rose by 4.1%, exceeding full-year guidance. Dupixent sales surpassed the 13 billion euro target, growing by …

msn.com

21%
OFF

Press Release: Sanofi Delivers Solid Sales And Business EPS Growth …

2 weeks from now

Full-year 2024 business EPS guidance. Sanofi expects 2024 business EPS (1) to remain roughly stable excluding the impact of an expected effective tax rate increase to 21% and decrease …

sanofi.com

3%
OFF

Press Release: Q4 Sales Growth Of 10.3%, 2024 Business EPS …

2 weeks from now

Jan 30, 2025 · Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4: sales growth of …

tradingview.com

$0.19
OFF

Lilly Reports Full Q4 2024 Financial Results And Provides 2025 …

2 weeks from now

1 day ago · EPS in Q4 2024 and Q4 2023 included acquired IPR&D charges of $0.19 and $0.62, respectively. Fourth-Quarter Non-GAAP Measures On a non-GAAP basis, Q4 2024 gross …

prnewswire.com

3%
OFF

Press Release: Q4 Sales Growth Of 10.3%, 2024 Business EPS

2 weeks from now

Jan 30, 2006 · In 2024, it is estimated that sales growth benefited by 1.8 percentage points. 6 Applying average January 2025 exchange rates, the currency impacts are estimated between …

sanofi.com

3%
OFF

Sanofi: Q4 Sales Growth Of 10.3%, 2024 Business EPS Guidance …

2 weeks from now

Jan 30, 2025 · Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales growth of …

finanznachrichten.de

2%
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook

2 weeks from now

3 days ago · Q4 2024: Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of $0.39 and adjusted diluted EPS of $0.61 Net sales of $525 …

qiagen.com

3%
OFF

Press Release: Q4 Sales Growth Of 10.3%, 2024 Business EPS …

2 weeks from now

Jan 30, 2025 · Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales growth of …

streetinsider.com

51%
OFF

AMD Reports Fourth Quarter And Full Year 2024 Financial Results

2 weeks from now

3 days ago · Fourth quarter revenue was a record $7.7 billion, gross margin was 51%, operating income was $871 million, net income was $482 million and diluted earnings per share was …

amd.com

$521
OFF

QIAGEN Delivers Solid Q4 2024 Growth Ahead Of Outlook

2 weeks from now

2 days ago · Q4 2024: Net sales of $521 million; diluted EPS of $0.39 and adjusted diluted EPS of $0.61 Net sales of $525 million CER ahead of outlook for at least $520 million CER and …

nasdaq.com

$103
OFF

Graphic Packaging Holding Company Reports Fourth Quarter And …

2 weeks from now

3 days ago · The decline was driven primarily by a $103 million negative impact from the divestiture of the Augusta, GA bleached paperboard manufacturing facility and bleached …

graphicpkg.com

13%
OFF

Lilly Reports Full Q4 2024 Financial Results And Provides 2025 …

2 weeks from now

1 day ago · Growth Products 2 revenue increased 13% to $5.95 billion in Q4 2024 driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales. The growth in …

lilly.com

5%
OFF

BCE Reports 2024 Q4 And Full-year Results, Announces 2025 …

2 weeks from now

1 day ago · Adjusted EBITDA 1 growth of 1.5% in Q4 delivered 0.9 percentage ... delivering a 3.9% increase in adjusted EPS to $0.79. For full-year 2024, ... increased sales of business …

prnewswire.com

FAQs about Press Release: Q4 sales growth of 10.3%, 2024 business EPS Coupon?

How did CER perform in Q4 2023?

Full-year 2023 delivered 5.3% sales growth and 5.4% business EPS growth at CER R&D transformation and Key milestones in Q4 Progress on Corporate Social Responsibility strategy in Q4 Full-year 2024 business EPS guidance ...

How did Sanofi's stock perform in Q4 2024?

Sanofi's stock showed a modest increase, reflecting investor confidence in its growth trajectory and strategic initiatives. Q4 2024 net sales increased by 10.3% to 10.6 billion euros. Business EPS rose by 4.1%, exceeding full-year guidance. Dupixent sales surpassed the 13 billion euro target, growing by 23%. ...

How does currency affect business EPs in 2024?

Applying average January 2024 exchange rates, the currency impact on 2024 business EPS is estimated between -3.5% to -4.5%. Paul Hudson, Sanofi Chief Executive Officer, commented: “2023 marked a critical year on our journey to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. ...

What is the Consolidated Income Statement for Q4 2023?

The consolidated income statement for Q4 2023 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (2) 2023 business EPS was €8.11; (3) Free cash flow is a non-IFRS financial measure (definition in Appendix 9). (4) Risk-adjusted net sales at CER . ...

How did obaggio's gross profit grow in 2024?

Gross profit grew by 10.3% at constant exchange rate to €31,100,000,000 with a gross margin of 75.7%. Our gross margin declined slightly due to the absence of any COVID revenue in 2024 and the remaining impact of the Obaggio LOE. ...

Where can I find the Q4 & full year 2024 conference call?

Moderator/Operator, Sanofi: Welcome to the Q4 and full year 2024 Conference Call for Investors and Analysts. As usual, you can find the slides on cenuver.com. Please turn to slide number 3. Here we have the usual forward looking statements. ...